Resources Archive - Page 25 of 52

Expanded Role of PDX Models in Anticancer Drug Development

Expanded Role of PDX Models in Anticancer Drug Development Patient-derived xenograft (PDX) models are established by implanting surgically resected patient...

Preclinical Evaluation of JAK Inhibitors in an Atopic Dermatitis Model

Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin condition that is characterized by recurrent eczematous lesions. Janus kinase (JAK)...

Rapamycin Ameliorates Renal Pathology in a Model of Passive Heymann Nephritis

Passive Heymann nephritis, induced by intravenous injection of anti-Fx1A in susceptible rat strains, is a complement-dependent model of glomerular disease...

Unveiling Mechanisms of CDK4-CDK6 Inhibitor Resistance in Breast Cancer Models

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Paclitaxel-Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...